AB206 (5,8-dihydro 5-methoxy-8-oxo-2H-1,3-dioxolo-4,5-g quinoline 7-carboxylic acid) is a novel antibacterial agent structurally related to nalidixic acid. AB206 has potent antibacterial activity against clinical isolates of gram-negative bacteria and is 4 to 18 times more active than nalidixic acid. AB206 inhibited the growth of Staphylococcus aureus and Pseudomonas aeruginosa, which were resistant to nalidixic acid. Cross-resistance was not observed between AB206 and various antibiotics, and most bacterial strains resistant to nalidixic acid were susceptible to AB206. AB206 showed bactericidal activity against Escherichia coli, Proteus, Klebsiella pneumoniae, and P. aeruginosa. Chemotherapeutic effects after oral administration of AB206 in mice experimentally infected with E. coli, K. pneumoniae, and Proteus morganii showed that AB206 was two to four times more potent than nalidixic acid.
Since the introduction of nalidixic acid (NA) (4) into practical use for the treatment of bacterial infection, many useful drugs of the same group, such as piromidic acid (PA) (6) , oxolinic acid (10) , and pipemidic acid (7) have been reported to be active against infections with gramnegative bacteria. The present compound, AB206, is a quinoline derivative similar to oxolinic acid and has potent antibacterial activity against gram-negative bacteria. This report deals with the results of an antimicrobial evaluation of AB206 against clinical isolates in vitro and in vivo in comparison with NA and PA.
MATERIALS AND METMODS Drugs. AB206 ( Fig. 1) was synthesized in the Research Department of the Pharmaceutical Division of Sumitomo Chemical Co., Ltd. The other drugs used for comparison were commercial products.
Media. Heart infusion agar (HIA; Eiken Chemical Co.) and brain heart infusion broth (BHI (Difco Laboratories) were used. Peptone water consisted of 10 g of peptone (Takeda Chemical Industries, Ltd.), 5 times more active than NA and PA, respectively.
The ID50 values of AB206 against Serratia marcescens and K. pneumoniae strains were 0.76 and 0.90,ug/ml, respectively; those of NA were 3.2 and 4.8 ,Ag/ml, and those of PA were 23 and 32 ,ug/ml, respectively. AB206 was about five times more active than NA against S. marcescens and K. pneumoniae.
The antibacterial activity of AB206 against P. aeruginosa is shown in Fig. 2c . Large differences were seen in the MIC distributions of AB206, NA, and PA against 150 P. aeruginosa strains; the MIC peaks of AB206 and NA were located at 12.5 and 100 ug/ml, respectively. AB206 was approximately eight times more active than NA.
With Staphylococcus aureus, the ID5o values of AB206, NA, and PA were 4.2, 28, and 5.8 tLg/ ml, respectively. AB206 was seven times more active than NA. The effect of inoculum size on the antibacterial activity of AB206 was studied. However, inoculum size did not significantly af- (Table 2 ). All of the antibiotic-resistant bacteria used were derived from clinical isolates. All were susceptible to AB206 and were inhibited by 0.4 to 1.6 ,tg of the drug per ml irrespective of their resistance to various other antibiotics.
The in vitro activity of AB206 against clinical isolates resistant to NA was examined. AB206 was moderately active against NA-resistant E. coli, P. morganii, P. vulgaris, P. rettgeri, P. mirabilis, K. pneumoniae, S. marcescens, and ANTIBACTERIAL ACTIVITY OF AB206 205 Shigella strains which were resistant to 200 tg or more of NA per ml (Table 3) . Against 135 NA-resistant bacteria (4 E. coli, 31 Proteus, 31 K. pneumoniae, 39 S. marcescens, and 30 Shigella strains) which were resistant to NA, the MIC distribution peak of AB206 was 3.13 ,Lg/ml (Fig. 3 ). These results demonstrate that crossresistance between AB206 and NA is incomplete.
Bactericidal activity. Bactericidal activity of AB206 against E. coli GN6288, Proteus morganii GN1867, and Pseudomonas aeruginosa GN6733 was examined by counting viable cells (Fig. 4) . AB206 P. morganii GN4382 GN4411 GN4738 GN4457
P. vulgaris GN7900 GN7914 
>200
wag of the drug per ml. AB206 displayed bactericidal action against gram-negative bacteria.
In vivo antibacterial activity. The therapeutic effects of AB206 were examined by using experimental infections of mice with gram-negative bacteria. The ED50 values ofAB206 against E. coli ML4707, K. pneumoniae ML4730, and P. morganii ML4731 were 8.9, 46.0, and 20.4 mg/ kg, respectively, and those of NA were 19.0, 187.0, and 47.8 mg/kg, respectively (Table 4) . AB206 displayed about two to four times greater activity than NA. staphylococci. We compared the antibacterial activity of AB206 with that of NA and of PA, using clinical isolates. AB206 had a broad antibacterial spectrum and was active against P. aeruginosa, which was resistant to PA and to NA. AB206 was 4 to 18 times more active than NA and 20 to 140 times more active than PA against gram-negative bacteria.
In vivo antibacterial activity of AB206 against gram-negative bacteria was 2 to 4 times greater than that of NA. Therefore, in vitro antibacterial activity of AB206 seemed to have reflected in vivo antibacterial activity of the drug. Recently, the isolation frequency of NA-resistant bacteria has also been increasing in clinical isolates of gram-negative bacteria (2) , although none with plasmid-encoding NA resistance has been found (9) . AB206 was active against most bacteria resistant to NA and PA. Therefore, it was considered that cross-resistance between AB206 and NA was incomplete. Resistance to AB206 in vitro did not develop as readily as to NA; also, the mutation frequency of AB206 was lower than that of NA (unpublished data). Moreover, NA and its analogs have been found to inhibit bacterial deoxyribonucleic acid synthesis (1, 3, 8) .
